← ANALYST RATINGS · TIPRANKS
LB Pharmaceuticals, Inc. (LBRX): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy1 Hold0 Sell
Ratings of 10 analysts in the last 3 months12-month forecast
Based on 10 price targets given in the last 3 months, the average target is $59.90, the highest $80.00, the lowest $35.00. The average is +63.0% from the last price of $36.74.
Analyst ratings 12
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $35.00 → $37.00+5.7% | Hold | +0.7% | Reiterated | 16.10.26on TipRanks 10:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $35.00 → $37.00+5.7% | Hold | +0.7% | Reiterated | 16.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $35.00 → $36.00+2.9% | Hold | −2.0% | Reiterated | 16.10.26on TipRanks 10:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $35.00 → $37.00+5.7% | Hold | +0.7% | Reiterated | 16.10.26on TipRanks 10:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $36.00 → $38.00+5.6% | Hold | +3.4% | Reiterated | 16.10.26on TipRanks 10:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $35.00 → $37.00+5.7% | Hold | +0.7% | Reiterated | 16.10.26on TipRanks 10:05 | — | |
| Name not given | — | $80.00 | Buy | +117.7% | Reiterated | 12.10.26on TipRanks 13:15 | −3.4%next day −3.2% | ↗ |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $60.00 | Buy | +63.3% | Reiterated | 12.10.26on TipRanks 06:30 | −3.4%next day −3.2% | ↗ |
| Sumant Kulkarni★★★★★★★★★★#670 · hits 50% · avg +14.2% | Canaccord Genuity | $65.00 | Buy | +76.9% | Initiated | 09.10.26on TipRanks 05:25 | +6.9%next day −3.4% · 5 days +0.7% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $80.00 | Buy | +117.7% | Initiated | 05.10.26on TipRanks Oct 6 05:45 | −7.1%next day −1.6% · 5 days +3.4% | ↗ |
| Boobalan Pachaiyappan★★★★★★★★★★#11894 · hits 38% · avg −7.5% | Roth MKM | $37.00 → $35.00−5.4% | Hold | −4.7% | Downgrade | 05.10.26on TipRanks 09:00 | −7.1%next day −1.6% · 5 days +3.4% | ↗ |
| Ami Fadia★★★★★★★★★★#73 · hits 59% · avg +36.1% | Needham | $68.00 | Buy | +85.1% | Initiated | 02.10.26on TipRanks 04:35 | −1.5%next day −7.1% · 5 days −0.5% | ↗ |
| Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% | Clear Street | $45.00 → $69.00+53.3% | Buy | +87.8% | Assigned | 21.08.26on TipRanks Aug 20 16:20 | +0.4%next day +1.5% · 5 days −0.2% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $40.00 → $53.00+32.5% | Buy | +44.3% | Reiterated | 13.08.26on TipRanks 07:35 | −3.1%next day +8.1% · 5 days +8.7% | ↗ |
| Adam Vogel★★★★★★★★★★#1113 · hits 79% · avg +38.0% | Craig-Hallum | $36.00 → $45.00+25.0% | Buy | +22.5% | Reiterated | 12.08.26on TipRanks 09:35 | −0.1%next day −3.1% · 5 days +8.3% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $78.00 | Buy | +112.3% | Reiterated | 03.08.26on TipRanks 07:15 | +5.5%next day +3.2% · 5 days +5.0% | ↗ |
| Malcolm Hoffman★★★★★★★★★★#7666 · hits 100% · avg +34.9% | BMO Capital | $46.00 | Buy | +25.2% | Initiated | 21.07.26on TipRanks Jul 27 16:54 | +3.7%next day +11.0% · 5 days +9.1% | ↗ |
| Rudy Li★★★★★★★★★★#235 · hits 63% · avg +76.1% | Wolfe Research | $45.00 | Buy | +22.5% | Initiated | 07.07.26on TipRanks 06:15 | +3.1%next day 0.0% · 5 days −7.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering LB Pharmaceuticals, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $56.57 at a price of $38.38 (+47.4%); now: $59.90 at $36.74 (+63.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 4 | 2 | 6 |
| Buy | 7 | 9 | 7 | 10 | 8 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.62 (from $-2.21 to $-1.07). Last quarter: $-1.71.
Best top-analyst consensus in the sector · General
About LB Pharmaceuticals, Inc.
- CEO: Heather D. Turner
- Employees: 49
- One Pennsylvania Plaza, New York, NY, 10119, US
- lbpharma.us
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Data from the stock’s TipRanks forecast page, read 14 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗